Sanofi/Regeneron’s PCSK9 Data Show Robust LDL Reduction, But Prompt Call For Outcomes Data
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novel inhibitor of PCSK9 lowers LDL cholesterol far beyond what can be achieved by statins. Investigators report reductions of 40% to 72% in new Phase II trial.